ZCA
PCRX icon

Zeke Capital Advisors’s Pacira BioSciences PCRX Stock Holding History

Zeke Capital Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$227K Buy
+5,875
New +$286K 0.01% 417

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Zeke Capital Advisors's PCRX Position: Q4 2022 in Review

Zeke Capital Advisors opened a new position in Pacira BioSciences (PCRX) in Q4 2022: 5,875 shares worth $227K. The stake represents 0.01% of the portfolio and ranks #417 among its holdings.

273 funds tracked by Wall St. Rank hold PCRX as of Q4 2022.

  • Zeke Capital Advisors held 5,875 shares of Pacira BioSciences worth $227K as of Q4 2022.
  • Pacira BioSciences was a new Zeke Capital Advisors position in Q4 2022.
  • Pacira BioSciences made up 0.01% of Zeke Capital Advisors's portfolio in Q4 2022, its #417 holding.
  • 273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.